Research Library
Padma 28 in patients with chronic hepatitis B - Clinical and immunological effects
Authors: Brzosko WJ
Source: SchweizZschr für GanzheitsMed 1992;7/8(Suppl 1):13-14
Since our first studies on the localization of the antigens (Hs Ag, Hbc Ag) of the hepatits B virus (HBV) there is now agreement that the inflammationary damage to the liver through chronically active hepatits B (CAH-B) is not the direct result of the virus but of the immune reaction of the organism against viral antigens. Thus chronic inflammatory reaction observed in the liver of patients with CAH-B means that the organism is unable to eliminate the viral infection of the hepatocytes through the immune reaction. This pathogenic viewpoint on CAH-B and other forms of chronic viral hepatitis (C,D) stimulated us to stop treating patients with immune-suppressive and anti-inflammatory medication.
After several years of attempting to treat patients with CAH-B with immuno-modulating compounds we came to the conclusion that the therapeutic use of the Padma 28 herbal remedy is the most suitable means of achieving a clinical, biochemical, immunological and histological benefit.
In the course of the past decade we have treated 126 adults and 52 children with CAH-B. Following a two-year treatment with Padma 28 (daily dose: 3 x 2 tablets) the following results were achieved: About 90% of the patients had their biochemical parameters normalized and the number of the T-lymphocyte subsets (CD3, CD4, CD8, CD4/CD8) improved. In about 15% of patients viral infection was eliminated. About 70% of patients seroconverted from Hbe-Ag positivity to anti-Hbe. In around 10% of the patients no clinical or serological improvement was observed following the treatment.
Padma 28 was well tolerated by the patients. Their appetite and general well being improved. Ultrasonographic tests of liver and spleen gave no indication of any cirrhotic lesions.